Loading...
Cipla Limited — Ras Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #1 for Ras · $8.3M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Ras with $8.3M in export value and 166 verified shipments. Cipla Limited holds a 2.7% market share in Ras exports across 21 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| IVORY COAST | $1.5M | 30 | 30.7% |
| PAKISTAN | $1.4M | 38 | 28.1% |
| SINGAPORE | $950.0K | 20 | 19.5% |
| HONG KONG | $350.0K | 7 | 7.2% |
| UNITED STATES | $335.0K | 117 | 6.9% |
| CHILE | $177.9K | 5 | 3.7% |
| BENIN | $50.0K | 1 | 1.0% |
| SUDAN | $50.0K | 1 | 1.0% |
| MOZAMBIQUE | $50.0K | 1 | 1.0% |
| BELGIUM | $28.7K | 34 | 0.6% |
Cipla Limited exports Ras to 32 countries. The largest destination is IVORY COAST accounting for 30.7% of Cipla Limited's Ras shipments, followed by PAKISTAN (28.1%) and SINGAPORE (19.5%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| PROGRAMME NATIONAL DE | IVORY COAST | $1.5M | 30 |
| JS BANK LTD, | PAKISTAN | $904.6K | 25 |
| SUCCESS INTER LINK PTE LTD | SINGAPORE | $700.0K | 14 |
| SUCCEED HOLDINGS LTD. | HONG KONG | $350.0K | 7 |
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $335.0K | 99 |
| JS BANK LTD | PAKISTAN | $297.7K | 7 |
India exported $123.4M worth of Ras through 15,000 shipments from 1156 suppliers to 176 countries, serving 2,323 buyers globally. Cipla Limited contributes $8.3M to this total, accounting for 2.7% of India's Ras exports. Cipla Limited ships Ras to 32 countries through 47 buyers.
Cipla Limited's average Ras shipment value is $50.0K per consignment, based on 166 shipments totaling $8.3M. The largest destination is IVORY COAST (30.7% of Cipla Limited's Ras exports).
Cipla Limited ranks #1 among 1156 Indian Ras exporters with a 2.7% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($36.5M), MSN LABORATORIES PRIVATE LIMITED ($22.3M), MYLAN LABORATORIES LIMITED ($20.1M). Cipla Limited processed 166 shipments to 21 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DOLUTEGRAVIRAS SODIUM+LAMIVUDINE+ TENOFOVIR DISOPROXIL FUMARATE TABLETS 50/300/300MG12960 Pack SZ 1X90'S=1166400 NOS | $600.0K | 12 |
| ODEROX 500 TAB (DT) (DEFERASIROX ) (INV. | $532.3K | 14 |
| DOLUTEGRAVIRAS SODIUM+LAMIVUDINE+ TENOFOVIR DISOPROXIL FUMARATE TABLETS 50/300/300MG13020 Pack SZ 1X90'S=1171800 NOS | $400.0K | 8 |
| DUPROST 0.5 MG CAPSULES (DUTRASTERIDE 0 | $350.0K | 7 |
| ODEROX 250 TAB DT ( DEFERASIROX DISPERSI | $150.6K | 4 |
| ODEROX 500 TAB DT DEFERASIROX INV | $100.0K | 2 |
| SANTIGRASE 50 MG TABLET DOLUTEGRAVIR TABLETS 50 MG 5292PACKSX1X30 S 158760NOS | $100.0K | 2 |
| DOLUTEGRAVIRAS SODIUM+LAMIVUDINE+TENOF | $100.0K | 2 |
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | MSN LABORATORIES PRIVATE LIMITED | $22.3M | 512 | 24 | $43.5K |
| 3 | MYLAN LABORATORIES LIMITED | $20.1M | 402 | 16 | $50.0K |
| 1 | CIPLA LIMITED ★ | $8.3M | 166 | 21 | $50.0K |
| 6 | ALKEM LABORATORIES LIMITED | $6.9M | 138 | 6 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,417 | 9.4% |
| DELHI AIR CARGO ACC (INDEL4) | 1,335 | 8.9% |
| NHAVA SHEVA SEA (INNSA1) | 947 | 6.3% |
| SAHAR AIR | 935 | 6.2% |
| DELHI AIR | 709 | 4.7% |
| Bombay Air | 648 | 4.3% |
| AHEMDABAD AIR ACC (INAMD4) | 528 | 3.5% |
| TUTICORIN SEA (INTUT1) | 406 | 2.7% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Ras, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Ras — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Ras exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
| SUCCESS INTER LINK PTE,LTD |
| SINGAPORE |
| $250.0K |
| 5 |
| JS BANK LTD. | PAKISTAN | $166.0K | 6 |
| MEGALABS CHILE S A | CHILE | $100.0K | 2 |
| MINTLAB | CHILE | $77.9K | 3 |
Cipla Limited supplies Ras to 47 buyers globally. The largest buyer is PROGRAMME NATIONAL DE (IVORY COAST), followed by JS BANK LTD, (PAKISTAN) and SUCCESS INTER LINK PTE LTD (SINGAPORE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| DUPROST 0.5MG CAPSULES DUTRASTERIDE 0.5MG 3000 PACK 10 X 10'S | $100.0K | 2 |
| DUPROST 0.5MG CAPSULES DUTRASTERIDE 0.5MG 2980 PACK 10 X 10'S | $100.0K | 2 |
Cipla Limited exports 88 distinct Ras formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DOLUTEGRAVIRAS SODIUM+LAMIVUDINE+ TENOFOVIR DISOPROXIL FUMAR with 12 shipments worth $600.0K.
| $50.0K |
| 7 | DR.REDDY'S LABORATORIES LTD | $6.0M | 119 | 12 | $50.0K |
Cipla Limited ranks #1 among 1156 Indian Ras exporters. Average shipment value of $50.0K compared to the market average of $106.8K. The closest competitors by value are MSN LABORATORIES PRIVATE LIMITED and MYLAN LABORATORIES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 176+ countries, 2,323+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ras. For current shipment-level data, contact TransData Nexus.